A joint team of central and state drug regulators in India will re-inspect 147 drug manufacturing plants that have been under scrutiny over the last two years, reports the Economic Times.
The team will conduct a risk-based inspection exercise to ensure that drug manufacturing plants have taken measures to improve product quality. Companies that were found non-compliant during the first round of inspections — initiated in 2016 — were allowed time to plug deficiencies.
The re-inspections are expected to occur in the next three weeks and may involve punitive action against firms not complying with prescribed good manufacturing practices.
Read the Economic Times coverage
